Histone deacetylase inhibitors are potent radiation protectants

Luca Paoluzzi, William D. Figg

Research output: Contribution to journalShort survey

14 Scopus citations

Abstract

Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deacetylase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.

Original languageEnglish (US)
Pages (from-to)612-613
Number of pages2
JournalCancer Biology and Therapy
Volume3
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

    Fingerprint

Keywords

  • Cutaneous radiation syndrome
  • Histone deacetylase inhibitors
  • Phenylbutyrate
  • Radiotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this